These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33923427)

  • 41. Gastric (gastrointestinal)-type endometrial adenocarcinoma presenting as a solitary endometrial polyp: a case report and literature review on a novel and potentially aggressive endometrial cancer histotype.
    Bragantini E; Angelico G; Disanto MG; Magri E; Maccio L; Barbareschi M
    Pathologica; 2023 Aug; 115(4):227-231. PubMed ID: 37711039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent Advances in Cervical Cancer Management: A Review on Novel Prognostic Factors in Primary and Recurrent Tumors.
    Santoro A; Inzani F; Angelico G; Arciuolo D; Bragantini E; Travaglino A; Valente M; D'Alessandris N; Scaglione G; Sfregola S; Piermattei A; Cianfrini F; Roberti P; Zannoni GF
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group.
    Zannoni GF; Bragantini E; Castiglione F; Fassan M; Troncone G; Inzani F; Pesci A; Santoro A; Fraggetta F
    Front Oncol; 2022; 12():805613. PubMed ID: 35463299
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Vulvar Immunohistochemical Panel (VIP) Project: Molecular Profiles of Vulvar Squamous Cell Carcinoma.
    Garganese G; Inzani F; Fragomeni SM; Mantovani G; Della Corte L; Piermattei A; Santoro A; Angelico G; Giacò L; Corrado G; Fagotti A; Zannoni GF; Scambia G
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential p16 expression levels in the liver, hepatocytes and hepatocellular cell lines.
    Kramar B; Šuput D; Milisav I
    PeerJ; 2021; 9():e12358. PubMed ID: 34760375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tissue-based Immunohistochemical Biomarker Accuracy in the Diagnosis of Malignant Glandular Lesions of the Uterine Cervix: A Systematic Review of the Literature and Meta-Analysis.
    Lee S; Rose MS; Sahasrabuddhe VV; Zhao R; Duggan MA
    Int J Gynecol Pathol; 2017 Jul; 36(4):310-322. PubMed ID: 27801764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Emerging Anti-p16 Antibody-BC42 Clone as an Alternative to the Current E6H4 for Use in the Female Genital Tract Pathological Diagnosis: Our Experience and a Review on p16ink4a Functional Significance, Role in Daily-Practice Diagnosis, Prognostic Potential, and Technical Pitfalls.
    Angelico G; Santoro A; Inzani F; Straccia P; Spadola S; Arciuolo D; Valente M; D'Alessandris N; Benvenuto R; Travaglino A; Raffone A; Zannoni GF
    Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33923427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. p16 expression in the female genital tract and its value in diagnosis.
    O'Neill CJ; McCluggage WG
    Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations.
    Negri G; Egarter-Vigl E; Kasal A; Romano F; Haitel A; Mian C
    Am J Surg Pathol; 2003 Feb; 27(2):187-93. PubMed ID: 12548164
    [TBL] [Abstract][Full Text] [Related]  

  • 50. P16(INK4a) protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: diagnostic and clinical considerations.
    Caponio MA; Addati T; Popescu O; Petroni S; Rubini V; Centrone M; Trojano G; Simone G
    Cancer Biomark; 2014; 14(2-3):169-75. PubMed ID: 24878818
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of p16INK4A in Pap smears containing atypical glandular cells from the uterine cervix.
    Nieh S; Chen SF; Chu TY; Lai HC; Fu E
    Acta Cytol; 2004; 48(2):173-80. PubMed ID: 15098536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patterns of SATB2 and p16 reactivity aid in the distinction of atypical polypoid adenomyoma from myoinvasive endometrioid carcinoma and benign adenomyomatous polyp on endometrial sampling.
    Worrell HI; Sciallis AP; Skala SL
    Histopathology; 2021 Jul; 79(1):96-105. PubMed ID: 33459390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathological features, immunoprofile and mismatch repair protein expression status in uterine endometrioid carcinoma: focus on MELF pattern of myoinvasion.
    Santoro A; Angelico G; Inzani F; Spadola S; Arciuolo D; Valente M; Musarra T; Capelli G; Fanfani F; Gallotta V; Scambia G; Zannoni GF
    Eur J Surg Oncol; 2021 Feb; 47(2):338-345. PubMed ID: 32788094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroendocrine Carcinoma of the Uterine Cervix: A Clinicopathologic and Immunohistochemical Study with Focus on Novel Markers (Sst2-Sst5).
    Inzani F; Santoro A; Angelico G; Feraco A; Spadola S; Arciuolo D; Valente M; Carlino A; Piermattei A; Scaglione G; Scambia G; Rindi G; Zannoni GF
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32408525
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.